- Home
- HG vs MYGN Comparison
HG vs MYGN Comparison
Compare HG & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HG | MYGN |
|---|---|---|
| Founded | 2013 | 1991 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 444.2M |
| IPO Year | 2023 | 1996 |
Fundamental Metrics
Financial Performance| Metric | HG | MYGN |
|---|---|---|
| Price | $34.04 | $5.96 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $32.00 | $7.64 |
| AVG Volume (30 Days) | 510.9K | ★ 1.6M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 6.26% | N/A |
| EPS Growth | ★ 51.23 | N/A |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $2,905,524,000.00 | $771,400,000.00 |
| Revenue This Year | $1.80 | $6.86 |
| Revenue Next Year | $12.52 | $5.45 |
| P/E Ratio | $25.92 | ★ N/A |
| Revenue Growth | ★ 24.70 | 2.33 |
| 52 Week Low | $20.47 | $3.53 |
| 52 Week High | $34.49 | $8.59 |
Technical Indicators
Market Signals| Indicator | HG | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 68.76 | 73.14 |
| Support Level | $28.44 | $4.29 |
| Resistance Level | N/A | $7.29 |
| Average True Range (ATR) | 0.80 | 0.33 |
| MACD | 0.30 | 0.16 |
| Stochastic Oscillator | 88.00 | 96.75 |
Price Performance
Historical ComparisonAbout HG Hamilton Insurance Group Ltd. Class B
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.